Log in

NASDAQ:ABMD - ABIOMED Stock Price, Forecast & News

$167.22
+2.42 (+1.47 %)
(As of 02/16/2020 04:00 PM ET)
Today's Range
$163.20
Now: $167.22
$168.09
50-Day Range
$164.80
MA: $179.57
$196.01
52-Week Range
$155.02
Now: $167.22
$364.31
Volume621,544 shs
Average Volume837,479 shs
Market Capitalization$7.53 billion
P/E Ratio31.43
Dividend YieldN/A
Beta0.47
ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorN/A
Current SymbolNASDAQ:ABMD
CUSIP00365410
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$769.43 million
Cash Flow$4.06 per share
Book Value$23.23 per share

Profitability

Net Income$259.02 million

Miscellaneous

Employees1,371
Market Cap$7.53 billion
Next Earnings Date5/7/2020 (Estimated)
OptionableOptionable

Receive ABMD News and Ratings via Email

Sign-up to receive the latest news and ratings for ABMD and its competitors with MarketBeat's FREE daily newsletter.


ABIOMED (NASDAQ:ABMD) Frequently Asked Questions

What is ABIOMED's stock symbol?

ABIOMED trades on the NASDAQ under the ticker symbol "ABMD."

How were ABIOMED's earnings last quarter?

ABIOMED, Inc. (NASDAQ:ABMD) announced its quarterly earnings results on Thursday, February, 6th. The medical equipment provider reported $1.51 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $1.09 by $0.42. The medical equipment provider earned $221.60 million during the quarter, compared to analysts' expectations of $226.92 million. ABIOMED had a net margin of 29.14% and a return on equity of 19.53%. The firm's revenue for the quarter was up 10.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.97 EPS. View ABIOMED's Earnings History.

When is ABIOMED's next earnings date?

ABIOMED is scheduled to release their next quarterly earnings announcement on Thursday, May 7th 2020. View Earnings Estimates for ABIOMED.

What guidance has ABIOMED issued on next quarter's earnings?

ABIOMED updated its FY 2020 Pre-Market earnings guidance on Thursday, February, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $846-877 million, compared to the consensus revenue estimate of $885.43 million.

What price target have analysts set for ABMD?

7 brokers have issued 1 year price objectives for ABIOMED's stock. Their forecasts range from $165.00 to $340.00. On average, they anticipate ABIOMED's stock price to reach $248.33 in the next twelve months. This suggests a possible upside of 48.5% from the stock's current price. View Analyst Price Targets for ABIOMED.

What is the consensus analysts' recommendation for ABIOMED?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ABIOMED in the last year. There are currently 1 sell rating, 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ABIOMED.

What are Wall Street analysts saying about ABIOMED stock?

Here are some recent quotes from research analysts about ABIOMED stock:
  • 1. According to Zacks Investment Research, "ABIOMED wrapped up fourth-quarter fiscal 2019 on a mixed note. Competition in the MedTech industry is intense. Pricing pressure and foreign currency headwinds persist. ABIOMED has underperformed the industry in a year’s time. However, the company continues to gain from its flagship Impella, which saw a strong quarter. Impella’s patient success stories and increasing global adoption are added positives. Revenues from Japan also skyrocketed in the quarter. Considerable expansion in the operating margin buoys optimism. Meanwhile, surging R&D expenses show increasing focus on innovation. In fact, the company continues to invest in training and education. The recent CE Mark of the Impella Connect is encouraging as well. The company’s balance sheet is debt-free." (5/8/2019)
  • 2. BTIG Research analysts commented, "Term; Trimming PT to $340 From $400 Abiomed missed estimates in the quarter, delivering sales of $207M, short of consensus’ $219M forecast. Most of the weakness was U.S. driven, due to a weak cath lab (also seen in peer results) and to a greater extent, mix disruption leading to mgmt’s disproportionate focus away from protected PCI/elective procedures. To reflect these pressures, mgmt’s initial FY20 outlook calls for revenue growth of 17-23%, 6% below what mgmt (and we) would’ve considered more likely (and exactly the exact magnitude of the FQ4 shortfall). Mgmt outlined a number of initiatives to address these issues and noted that April is reportedly promising. The fact that mgmt still remains confident in addressable market and has left room to revise guidance during its next earnings call suggest there is good chance of upside." (5/7/2019)

Has ABIOMED been receiving favorable news coverage?

Media coverage about ABMD stock has trended somewhat positive this week, InfoTrie Sentiment reports. The research firm rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ABIOMED earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned headlines about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for ABIOMED.

Are investors shorting ABIOMED?

ABIOMED saw a decrease in short interest during the month of January. As of January 31st, there was short interest totalling 4,020,000 shares, a decrease of 6.9% from the January 15th total of 4,320,000 shares. Based on an average daily volume of 894,000 shares, the days-to-cover ratio is presently 4.5 days. Approximately 9.1% of the shares of the stock are sold short. View ABIOMED's Current Options Chain.

Who are some of ABIOMED's key competitors?

What other stocks do shareholders of ABIOMED own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ABIOMED investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Arista Networks (ANET), Align Technology (ALGN), Square (SQ), Netflix (NFLX), bluebird bio (BLUE), Intuitive Surgical (ISRG) and Adobe (ADBE).

Who are ABIOMED's key executives?

ABIOMED's management team includes the folowing people:
  • Mr. Michael R. Minogue, Chairman, CEO & Pres (Age 52)
  • Dr. David M. Weber, Chief Operating Officer (Age 58)
  • Mr. Michael G. Howley, VP & GM of Global Sales (Age 55)
  • Mr. William J. Bolt, Exec. Officer (Age 67)
  • Mr. Ian McLeod, VP & Corp. Controller

Who are ABIOMED's major shareholders?

ABIOMED's stock is owned by many different of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (6.04%), Sands Capital Management LLC (5.42%), Renaissance Technologies LLC (5.16%), State Street Corp (4.56%), William Blair Investment Management LLC (1.43%) and Credit Suisse AG (1.36%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Martin P Sutter, Michael G Howley, Michael R Minogue and William J Bolt. View Institutional Ownership Trends for ABIOMED.

Which major investors are selling ABIOMED stock?

ABMD stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Amundi Pioneer Asset Management Inc., Victory Capital Management Inc., Victory Capital Management Inc., Villere ST Denis J & Co. LLC, William Blair Investment Management LLC, Bank of New York Mellon Corp and Blair William & Co. IL. Company insiders that have sold ABIOMED company stock in the last year include David M Weber and Martin P Sutter. View Insider Buying and Selling for ABIOMED.

Which major investors are buying ABIOMED stock?

ABMD stock was purchased by a variety of institutional investors in the last quarter, including Sands Capital Management LLC, Credit Suisse AG, Jackson Square Partners LLC, Renaissance Technologies LLC, Bessemer Group Inc., Global Thematic Partners LLC, State Street Corp and ArrowMark Colorado Holdings LLC. View Insider Buying and Selling for ABIOMED.

How do I buy shares of ABIOMED?

Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is ABIOMED's stock price today?

One share of ABMD stock can currently be purchased for approximately $167.22.

How big of a company is ABIOMED?

ABIOMED has a market capitalization of $7.53 billion and generates $769.43 million in revenue each year. The medical equipment provider earns $259.02 million in net income (profit) each year or $3.60 on an earnings per share basis. ABIOMED employs 1,371 workers across the globe.View Additional Information About ABIOMED.


MarketBeat Community Rating for ABIOMED (NASDAQ ABMD)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  502 (Vote Outperform)
Underperform Votes:  450 (Vote Underperform)
Total Votes:  952
MarketBeat's community ratings are surveys of what our community members think about ABIOMED and other stocks. Vote "Outperform" if you believe ABMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel